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Abstract
Background: Preterm prelabour rupture of membranes (PPROM) complicates up to 2% of all pregnancies and is the cause of
40% of all preterm births. The optimal management of women with PPROM prior to 37 weeks, is not known. Furthermore,
diversity in current clinical practice suggests uncertainty about the appropriate clinical management.
There are two options for managing PPROM, expectant management (a wait and see approach) or early planned birth. Infection
is the main risk for women in which management is expectant. This risk need to be balanced against the risk of iatrogenic
prematurity if early delivery is planned. The different treatment options may also have different health care costs. Expectant
management results in prolonged antenatal hospitalisation while planned early delivery may necessitate intensive care of the
neonate for problems associated with prematurity.
Methods/Design: We aim to evaluate the effectiveness of early planned birth compared with expectant management for
women with PPROM between 34 weeks and 366 weeks gestation, in a randomised controlled trial. A secondary aim is a cost
analysis to establish the economic impact of the two treatment options and establish the treatment preferences of women with
PPROM close to term.
The early planned birth group will be delivered within 24 hours according to local management protocols. In the expectant
management group birth will occur after spontaneous labour, at term or when the attending clinician feels that birth is indicated
according to usual care. Approximately 1812 women with PPROM at 34–366 weeks gestation will be recruited for the trial.
The primary outcome of the study is neonatal sepsis. Secondary infant outcomes include respiratory distress, perinatal mortality,
neonatal intensive care unit admission, assisted ventilation and early infant development. Secondary maternal outcomes include
chorioamnionitis, postpartum infection treated with antibiotics, antepartum haemorrhage, induction of labour, mode of delivery,
maternal satisfaction with care, duration of hospitalisation, and maternal wellbeing at four months postpartum.
Discussion: This trial will provide evidence on the optimal care for women with PPROM close to term (34–37 weeks
gestation). Consideration of both the clinical and economic sequelae of the management of PPROM will enable informed
decision making and guideline development.
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Prelabour rupture of the membranes (rupture of the
membranes prior to the onset of labour) occurs in 20% of
all births and 40% of all preterm births [1-3]. When prela-
bour rupture of the membranes occurs at term there is
good evidence that early delivery is associated with a
lower incidence of maternal infection and increased
maternal satisfaction compared with expectant manage-
ment [2]. However, the optimal management of women
with preterm prelabour rupture of membranes (PPROM)
prior to 37 weeks, is not known.
PPROM near term: a management dilemma
Following membrane rupture the preterm fetus is at risk
of a number of complications such as: prematurity, pla-
cental abruption, ascending infection, intrapartum fetal
distress and cord prolapse [4-6]. Abruptio placentae com-
plicates pregnancy for 5–6% of women with PPROM [5].
As histological chorioamnionitis is more common in
women with pregnancies complicated with PPROM com-
pared with preterm or term controls [7], infection is the
main risk for women in which management is expectant.
These risks need to be balanced against the attendant risk
of iatrogenic prematurity if early delivery is planned.
At extreme preterm gestations (less than 30 weeks), in the
absence of maternal or fetal compromise, there is una-
nimity in that expectant management to allow further
fetal maturation is desirable [8]. This is because the pre-
term fetus born prior to 30 weeks has increased risk of
neonatal mortality, intraventricular haemorrhage, hyaline
membrane disease and necrotizing enterocolitis. These
risks, associated with immaturity, are reduced as the ges-
tational age extends beyond 30 weeks [9].
At gestations nearer to term the benefit to the fetus of
pregnancy prolongation following PPROM is uncertain
such that by 34 weeks it has been suggested that there is
no longer benefit for the fetus in the face of risks of intra-
uterine infection [10]. Decisions to electively deliver a
fetus preterm however require grounding in good clinical
evidence as mild prematurity is associated with a signifi-
cant health burden [11]. On the other hand, expectant
management means mothers are often hospitalised for
prolonged periods with the consequent health budgetary
implications.
Fetal and neonatal risks at 34–37 weeks gestation
Clinical decision-making requires consideration of the
potential risks and benefits of induction of labour against
expectant management with delivery at term or when
complications such as chorioamnionitis intervene neces-
sitating delivery. The aim of such management is to max-
imise the benefits of fetal maturity while avoiding the
potential harms of remaining in utero. At gestations
between 34 and 37 weeks, whilst the neonate is poten-
tially at increased risk of respiratory distress, difficulty
with thermoregulation and difficulty with breast feeding
these risks need to be balanced against the increased inci-
dence of chorioamnionitis associated with expectant
management in women with PPROM [2]. Histological
evidence of chorioamnionitis is present in up to 50% of
women who give birth preterm and is often not associated
with clinical symptoms or signs [12]. Chorioamnionitis is
a known significant risk factor for the neonate for the
development of cerebral palsy [12,13]. It is possible that
there are increased risks of long term adverse neurological
outcomes in those infants whose mothers are managed
expectantly with PPROM by increasing their duration of
exposure to often subclinical chorioamnionitis.
Systematic review of the evidence on care of PPROM <37 
weeks
We have published a protocol for a Cochrane systematic
review of randomised controlled trials to assess immedi-
ate delivery compared with expectant care in women with
ruptured membranes between 34 and 37 weeks [14]. Our
MEDLINE search used the terms (premature or preterm)
and (rupture of membranes) or 'PROM' and (induction of
labour) and randomised controlled trial) and identified
three randomised controlled trials (outlined below) that
we have included in a meta-analysis (Table 1).
Spinnato studied 47 patients with PPROM who had doc-
umented fetal lung maturation and randomised them to
immediate or delayed delivery [15]. Expectant manage-
ment was associated with increased maternal sepsis but
the study lacked power to detect any significant neonatal
Table 1: Meta-analysis of three trials comparing early planned delivery versus expectant management for preterm premature 
ruptured membranes between 34–37 weeks.
Outcome No. of Trials No. of Women Immediate 
Delivery
Expectant Care RR (95% CI)
Caesarean Section 2 140 8/72 (11.1%) 6/68 (8.8%) 1.21 (0.45 – 3.28)
Chorioamnionitis 3 260 8/129 (6.2%) 31/131 (23.6%) 0.25 (0.12 – 0.53)
Neonatal Sepsis 3 257 9/128 (7.0%) 8/129 (6.2%) 1.00 (0.41 – 2.45)
RDS 3 257 5/128 (3.9%) 3/129 (2.3%) 1.56 (0.41 – 5.97)
Perinatal Mortality 3 260 2/129 (1.6%) 2/131 (1.5%) 1.24 (0.19 – 8.06)Page 2 of 8
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significant 52% increase in maternal infectious morbidity
with expectant management but a similar incidence of
abdominal delivery and neonatal infection [16]. Both
Spinnato and Mercer required amniocentesis and bio-
chemical suggestion of pulmonary maturity prior to being
eligible in the study [15,16].
Naef et al randomised 120 women to expectant manage-
ment or immediate delivery and found no clinically sig-
nificant neonatal advantages to expectant management of
ruptured membranes at this gestational age [17]. Addi-
tionally there was a decrease in antepartum hospitaliza-
tion in those women randomized to immediate delivery.
The sample size was insufficient to detect changes in sep-
sis or potentially clinically significant differences in respi-
ratory distress.
Overall, there was insufficient power to detect differences
in important endpoints such as neonatal sepsis, respira-
tory distress, newborn intensive care resource use or eco-
nomic outcomes (Table 1). Although no differences in
neonatal sepsis were seen, the systematic review suggests
that over 1 in 20 babies exposed to PPROM at 34–37
weeks are at risk of neonatal sepsis (Table 1). Although
immediate delivery was associated with a significant
decrease in chorioamnionitis compared with those preg-
nancies that were managed expectantly, chorioamnionitis
is an intermediate histological outcome and does not nec-
essarily reflect maternal or infant morbidity. Thus there is
insufficient evidence on the benefits and harms of imme-
diate delivery compared with expectant care for women
with ruptured membranes between 34 and 37 weeks ges-
tation to make recommendations for clinical practice. Fur-
ther trials are necessary that should be of high quality,
assess serious maternal and infant morbidity, assess the
costs of care and provide information on neurodevelop-
ment at childhood follow up.
Current clinical practice in the management of PPROM in 
Australia and New Zealand
In a recent survey of the Fellows and Members of the
Royal Australian and New Zealand College of Obstetri-
cians and Gynaecologists, we found there was no consen-
sus on the management of PPROM [8]. In women who
rupture their membranes at gestations greater than 34
weeks, 49% of obstetricians would manage these women
expectantly with the patients remaining in hospital, while
51% of obstetricians would plan to deliver these women
prior to term. This demonstrates the current diverse
approach to the care of women with PPROM at greater
than 34 weeks gestation, suggests that there is clinical
equipoise and demonstrates the appropriateness of a clin-
ical trial. Furthermore, 65% of the responding obstetri-
cians would be willing to enrol women in a randomised
controlled trial of the management of PPROM at gesta-
tions greater than 34 weeks.
Resource and cost implications of planned early delivery 
and expectant management of PPROM
Expectant management may result in prolonged antenatal
hospitalization, with antibiotic treatment and regular
monitoring, and intensive care of the neonate in the event
of sepsis. On the other hand, planned early delivery may
necessitate intensive care of the neonate for problems
associated with prematurity (eg respiratory distress).
While some data are available for the US[18,19] and the
UK[20], it is not known whether there are differences in
the overall cost of care in the Australian setting. However,
it is likely that the biggest drivers of health system costs
will be the number of days admitted to hospital, particu-
larly neonatal intensive care.
The trial is designed and sufficiently sized to detect a clin-
ically significant difference in neonatal sepsis. We do not,
however, expect differences in mortality or long-term
morbidity between planned early delivery and expectant
management. In the absence of differences in these final
clinical outcomes, optimal treatment decisions will also
require information about comparative resource use, and
information about the preferences of women with
PPROM. The secondary aim of the project is therefore to
conduct a cost analysis of planned early delivery versus
expectant management of PPROM and to establish the
treatment preferences of women with PPROM.
Planned early delivery and expectant management repre-
sent very different experiences for the women involved.
Currently, the relative importance to women of the
attributes (health and non-health outcomes and process
attributes) of the treatment alternatives is unknown. Dis-
crete choice methodology takes into account the prefer-
ences of the mother and has been previously used to
explore preferences in a number of relevant areas includ-
ing intrapartum care[21], miscarriage[22], labour induc-
tion[23] and IVF[24]. Maternal preference is likely to
assume more importance in the choice of management




The primary aim of the project is to conduct a randomised
controlled trial to answer the clinical question: In women
with preterm prelabour ruptured membranes (PPROM)
between 34 weeks and 366 weeks gestation is planned
early delivery compared with expectant management
associated with less neonatal and maternal morbidity?Page 3 of 8
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the outcomes to establish the economic impact of
planned early delivery compared with expectant manage-
ment. The economic analysis will determine:
• the net impact of each intervention on hospital
resources.
• which attributes of the treatment alternatives (such as
time in hospital, risk of adverse outcomes, continuity of
care etc) are important to women.
• the relative importance of these attributes.
• the extent to which women are prepared to make trade-
offs between attributes.
Hypotheses
The primary hypotheses are that early planned delivery of
women with PPROM close to term is associated with:
1. less short-term neonatal and maternal morbidity com-
pared with expectant management.
2. fewer economic costs compared with expectant man-
agement.
3. no difference in long term morbidity or mortality
Study design
We will use a randomised controlled clinical trial to assess
the impact of early planned birth versus expectant man-
agement.
Setting
The study will be carried out in participating tertiary
obstetric, metropolitan and rural hospitals with facilities
to manage deliveries at or greater than 34 weeks.
Participants/Eligibility criteria
Pregnant women between 34 and 366 weeks gestation
with PPROM and a singleton pregnancy will be invited to
participate in the trial. Women with ruptured membranes
prior to 34 weeks gestation will become eligible at 34
weeks should their latency period extend to this gestation.
Rupture of the membranes will be determined clinically
and/or confirmed by a positive amnicator swab per-
formed at the time of speculum examination. Gestational
age will be determined by last menstrual period and/or by
early ultrasound if there is a discrepancy of more than 7
days to that of the estimated date of confinement from the
last menstrual period.
Exclusion criteria
Women who are in established labour, have clinical evi-
dence of chorioamnionitis or other indications for imme-
diate delivery such as meconium staining of the liquor or
an antepartum haemorrhage or any other contraindica-
tion to expectant management will be excluded from the
study. The presence of Group B streptococcus on urine or
genital tract culture will not be a specific indication for
exclusion from the study.
Procedures, recruitment, randomisation and collection of 
baseline data
Eligible women will be identified by a local research co-
ordinator and staff. Eligible women will be given the trial
information sheet, counselled and encouraged to discuss
the trial with her family. Once women have consented to
be involved in the trial, their entry details will be recorded
on a trial entry form and they will be randomised via a
central telephone randomisation service to one of two
treatment groups, early planned birth or expectant man-
agement.
The randomisation schedule will be prepared by a
researcher not involved with treatment allocation. Ran-
domisation will be 1:1, in balanced variable blocks and
stratified by centre.
All women will have baseline demographic, past obstetric
and medical histories recorded. Maternal temperature will
be recorded at a time as close to randomisation as possi-
ble. A vaginal swab will be collected from each participat-
ing woman and a fetal heart rate tracing obtained.
Antibiotic administration is regarded as best practice in
women presenting with PPROM and these should be
administered in accordance with the policy of the partici-
pating centre [25]. At the collaborating centres, data col-
lection will be the responsibility of the local research
coordinator.
Intervention
Early planned delivery group
Those women randomised to early planned birth will
have delivery scheduled as close to randomisation as pos-
sible and preferably within 24 hours of randomisation.
The mode of birth will be determined by usual obstetric
indications. Antibiotics should be continued in the intra-
partum period.
Expectant management group
In women randomised to expectant management birth
will occur after spontaneous labour, at term or when the
attending clinician feels that birth is indicated according
to usual care.Page 4 of 8
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obstetric team with care of the infant by the attending
neonatologist.
Follow up of women and infants in both treatment groups
At birth arrangements should be made for the placenta to
be examined histologically for chorioamnionitis and
funisitis. The histological examiners will be blinded to
treatment allocation. After birth, information will be
obtained relating to birth and infant outcomes from the
woman's and infant's case notes by the local research
coordinator. A full blood count (FBC) will be collected on
all babies with clinical signs consistent with bacterial, fun-
gal or yeast infection and on all babies commenced on
antibiotics. Four month questionnaires will be posted out
to assess maternal wellbeing, satisfaction with care, breast
feeding duration and early infant development.
Outcome measures
Baseline data collection
To assess the comparability of the study groups, baseline
demographic and medical information will be collected
from the medical record at the time of entry into the
study.
Primary outcome measure
The primary outcome will be the incidence of neonatal
sepsis. Sepsis will be classified as either definite or proba-
ble by an adjudication committee who will be unaware of
the allocation group.
Definite systemic neonatal infection will be defined as
the presence of clinical signs of infection and a positive
culture of a known pathogen from blood or cerebrospinal
fluid. For organisms of low virulence and/or high likeli-
hood of skin contamination of the blood culture, such as
coagulase negative staphylococcus, both a positive blood
culture and an abnormal full blood count (FBC) are
required.
Clinical signs of infection include respiratory distress,
apnoea, lethargy, abnormal level of consciousness circula-
tory compromise (including hypotension, poor per-
fusion, need for ionotropic support or volume
expansion), poor feeding and/or temperature instability.
An abnormal FBC count includes an abnormal white cell
count, low platelet count, abnormal neutrophil count,
raised immature neutrophil count, raised immature to
total neutrophil ratio and/or degenerative morphological
changes to neutrophils (toxic granulation or vacuoliza-
tion).
Probable neonatal infection will be defined as the pres-
ence of clinical signs of infection where the baby was
treated with antibiotics for 5 or more days together with
one or more of: an abnormal FBC; an abnormal acute
phase reactant (including C reactive protein [CRP] or pos-
itive Group B Streptococcal [GBS] antigen on bladder tap
urine, blood or cerebrospinal fluid); growth of a known
virulent pathogen (GBS, E. coli, Listeria) from surface




will include respiratory distress, perinatal mortality, dura-
tion of stay in a neonatal intensive or special care unit,
duration of stay in hospital, birth weight, Apgar score at 5
minutes, any assisted ventilation, early infant develop-
ment as measured by the women at four months (cor-
rected age) using the ages for stages questionnaire [26].
Secondary maternal outcomes
will include antepartum, intrapartum and postpartum
outcomes. Antepartum outcomes include chorioamnioni-
tis, antepartum haemorrhage, thrombosis /thromboem-
bolism, cord prolapse, treatment with antibiotics, and
health service utilisation including laboratory tests, fetal
well-being investigations and duration of hospitalisation.
Intrapartum outcomes include induction of labour, failed
induction of labour, caesarean section, assisted vaginal
delivery, intrapartum bleeding or intrapartum fever and
treatment with antibiotics. Placental swabs and histology
will also be collected if available. Postpartum outcomes
including postpartum infection treated with antibiotics,
thrombosis/thromboembolism duration of hospitalisa-
tion, and initiation of breast feeding will be obtained
from hospital records. Maternal satisfaction with care,
maternal wellbeing, anxiety, and postnatal depression,
and duration of breast feeding will be assessed at four
months postpartum using self-report questionnaires.
Maternal wellbeing will be assessed using the SF36 Health
Survey Questionnaire [27]. SF-36 data will be examined as
a single item measure of health and also by the Physical
Component Summary and the Mental Component Sum-
mary. The scores for women randomised to immediately
delivery and expectant care will be compared at baseline
and at 4 months postpartum. Anxiety will be measured by
the state component of the short Spielberger anxiety scale
which has been extensively used and validated [28]. Post-
natal depression will be assessed using the 10-item Edin-
burgh Postnatal Depression Scale, a self-report measure of
depression developed for use in the postpartum period
[29].
Economic evaluation
The economic questions being addressed in this study are
"given the equivalence in long term morbidity and mor-
tality between immediate delivery and expectant manage-Page 5 of 8
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alternative from the viewpoint of a health care funder"?
and "what are the (utility-based) preferences of women
with PPROM for their clinical management"? A cost anal-
ysis will be conducted in accordance with the methods
outlined by Drummond et al 1997 [30]. This will involve
an initial analysis on what resource utilization data can be
collected on the patient case report forms, from patient
medical records and from routine data collection. It is
likely that the biggest drivers of cost will be the number of
days admitted to hospital, particularly neonatal intensive
care. The methodology for hospital cost will include
micro-costing (where differences in resource utilization
between patient groups are likely to be important to the
final results) and components of case mix cost weights
(where utilization is more likely to be similar within
patient groups).
Discrete choice methods will be used to establish mater-
nal preferences, using established methods [31]. We will
generate a questionnaire based on pair-wise choices simi-
lar to the example shown in Table 2. The questionnaire
will be administered in face-to-face interviews with a sam-
ple of women enrolled in the PPROMT trial. A determin-
istic sensitivity analysis will be employed where
individual parameters are varied one at a time. A random
effects probit regression analysis will be used to analyse
patient responses to the discrete choice survey, identifying
which attributes are important, and the trade-offs
between attributes that women are prepared to make.
Statistical issues
Sample size
The trial is designed to demonstrate a 50% reduction in
proven or probable neonatal sepsis from 5% in those
women managed expectantly to 2.5% in those women
managed with immediate delivery. This requires a total
sample size of 1812 women with 80% power and a signif-
icance level of p = 0.05. The estimated neonatal sepsis rate
of 5% is based on discussions with neonatologists and is
conservative compared with the systematic review (6.2%
in control arms, where a 50% reduction would require
1448 women). For women who agree to participate we
expect almost complete follow-up on the primary out-
comes as these will be obtained from the medical records.
This sample size will also have adequate power to demon-
strate an increase in the need for ventilatory support from
4% in the expectant arm to 7% in the immediate delivery
arm.
Data analysis
Analyses will be by intention to treat, including withdraw-
als and losses to follow-up. Study groups will be com-
pared in terms of baseline characteristics. As this is a
randomised trial, we would anticipate minimal differ-
ences in baseline characteristics. If however, important
differences are found, these potential confounders will be
adjusted for in the analysis of outcomes. For the primary
outcome, the relative risk (and 95% confidence interval)
of neonatal sepsis in the early planned delivery group
compared with the expectant group will be calculated. If
adjustment for confounding is necessary logistic regres-
sion will be used. The secondary outcomes will be com-
pared using chi-square tests of significance for categorical
data and t-tests for continuous data. If adjustment for con-
founding is necessary logistic regression and multiple lin-
ear regression will be used respectively.
Interim analysis
An interim analysis by an independent data monitoring
committee with established terms of reference will be con-
ducted when 50% of women have been recruited. If there
is proof beyond reasonable doubt that an arm of the study
is either clearly indicated or contra-indicated, the trial will
be stopped prematurely. A difference of at least three
standard deviations in interim analysis of a major end-
point is needed to justify stopping the trial. All perinatal
deaths will be reviewed by a multidisciplinary adverse
events committee blinded to treatment allocation.
Ethical considerations
To date the study has been approved by the following eth-
ics committees: Northern Sydney and Central Coast Area
Health Service for the Royal North Shore and Hornsby
Kuringgai Hospitals (Ref. No. 0306-126M), University of
Adelaide at the Women's & Children's Hospital (Ref. No.
REC 1531/11/2006), Ramsay Health for North Shore Pri-
vate Hospital (Ref. No. 0306-126M), University of Sydney
Table 2: Example of a discrete choice question with pair-wise choices
Early planned birth Wait for labour
Time in hospital prior to giving birth No time 2 weeks
Likelihood of spontaneous vaginal birth X% Y%
Time mother spends in hospital after giving 
birth
1 week 3 weeks
Time baby spends in neonatal intensive car 2 weeks No time
Which would you choose? (Please circle one 
only)
Early planned birth or Wait for labourPage 6 of 8
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ney South West Area Health Service Ethics Review Com-
mittee for the Royal Prince Alfred Hospital (Protocol No.
X04-0167), Western Sydney Area Health Service for West-
mead Hospital (Ref. No. HREC2005/2/4.23(2028)) and
Nepean Hospital (Ref. No. HREC2005/2/4.23(2028)),
Townsville Health Service District (Ref. No. 43/05).
Confidentiality and data security
Participants in the trial will be identified by a study
number only, with a master code sheet linking names
with numbers being held securely and separately from the
study data. To ensure that all information is secure, data
records will be kept in a secure location at the Royal North
Shore Hospital in Sydney and accessible only to research
staff. As soon as all follow-up is completed the data
records will be de-identified. De-identified data will be
used for the statistical analysis and all publications will
include only aggregated data.
The electronic version of the data will be maintained on a
computer protected by password. All hard copy patient
identifiable data and electronic backup files will be kept in
locked cabinets, which are held in a locked room accessed
only by security code and limited staff. Data files will be
stored for 7 (seven) years after completion of the project
as recommended by the National Health and Medical
Research Council (NHMRC). Disposal of identifiable
information will be done through the use of designated
bags and/or a shredding machine.
Discussion
Outcomes and significance
At gestations remote from term, expectant management is
appropriate to allow fetal maturation. When PPROM
complicates pregnancies closer to term the risks of prema-
turity are lower and the risk to the infant of sepsis
becomes of greater significance. This trial will provide evi-
dence on the optimal care for women with PPROM close
to term (34–37 weeks gestation). If it can be demon-
strated that early planned birth in this clinical situation is
associated with less maternal and neonatal morbidity this
will change current practice. The findings of the study will
also have significant resource implications as PPROM
close to term is a frequent indication for antenatal admis-
sion. The trial allows for a detailed assessment of the costs
associated with the care of the neonate from the two dif-
ferent care strategies. Given the null hypothesis of no dif-
ferences between planned early birth and expectant
management in mortality or long-term morbidity, infor-
mation about preferences will allow women and their cli-
nicians to make optimal treatment choices. Information
about both preferences and costs will assist policymakers
in deciding if, and how, treatment options are presented
to women with PPROM. The results of the economic eval-
uation are thus expected to improve both clinical deci-
sion-making and the management of hospital resources.
Therefore, analysis of both the clinical and economic
sequelae of immediate birth as opposed to expectant
management will enable informed decisions and guide-
lines to be formulated.
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PPROM – preterm prelabour rupture of the membranes
FBC – full blood count
CRP – C reactive protein
GBS – Group B Streptococcus
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